Published in Mol Neurodegener on April 30, 2007
Non-cell autonomous toxicity in neurodegenerative disorders: ALS and beyond. J Cell Biol (2009) 5.65
Sustained therapeutic reversal of Huntington's disease by transient repression of huntingtin synthesis. Neuron (2012) 4.48
Full-length human mutant huntingtin with a stable polyglutamine repeat can elicit progressive and selective neuropathogenesis in BACHD mice. J Neurosci (2008) 3.54
Heterogeneity of CNS myeloid cells and their roles in neurodegeneration. Nat Neurosci (2011) 3.06
Glial cells as intrinsic components of non-cell-autonomous neurodegenerative disease. Nat Neurosci (2007) 3.02
Accumulation of N-terminal mutant huntingtin in mouse and monkey models implicated as a pathogenic mechanism in Huntington's disease. Hum Mol Genet (2008) 1.70
Pathophysiology of Huntington's disease: time-dependent alterations in synaptic and receptor function. Neuroscience (2011) 1.62
Protein aggregates in Huntington's disease. Exp Neurol (2011) 1.46
In vivo expression of polyglutamine-expanded huntingtin by mouse striatal astrocytes impairs glutamate transport: a correlation with Huntington's disease subjects. Hum Mol Genet (2010) 1.34
Intercellular (mis)communication in neurodegenerative disease. Neuron (2012) 1.31
Dysfunctional cell-cell signaling in the neurovascular unit as a paradigm for central nervous system disease. Stroke (2008) 1.29
Mutant huntingtin in glial cells exacerbates neurological symptoms of Huntington disease mice. J Biol Chem (2010) 1.25
Neuroinflammation in Huntington's disease. J Neural Transm (Vienna) (2010) 1.16
Neuroprotective effects of inositol 1,4,5-trisphosphate receptor C-terminal fragment in a Huntington's disease mouse model. J Neurosci (2009) 1.14
Genetic mouse models of Huntington's disease: focus on electrophysiological mechanisms. ASN Neuro (2010) 1.03
Role of cerebral cortex in the neuropathology of Huntington's disease. Front Neural Circuits (2013) 1.02
Brain networks in Huntington disease. J Clin Invest (2011) 1.02
A critical window of CAG repeat-length correlates with phenotype severity in the R6/2 mouse model of Huntington's disease. J Neurophysiol (2011) 1.01
Cannabinoid receptor 2 signaling in peripheral immune cells modulates disease onset and severity in mouse models of Huntington's disease. J Neurosci (2012) 1.00
Huntington's disease and the striatal medium spiny neuron: cell-autonomous and non-cell-autonomous mechanisms of disease. Neurotherapeutics (2012) 0.98
Neocortical expression of mutant huntingtin is not required for alterations in striatal gene expression or motor dysfunction in a transgenic mouse. Hum Mol Genet (2008) 0.96
High-content chemical and RNAi screens for suppressors of neurotoxicity in a Huntington's disease model. PLoS One (2011) 0.95
Ginsenosides protect striatal neurons in a cellular model of Huntington's disease. J Neurosci Res (2009) 0.94
Caenorhabditis elegans as a model system for studying non-cell-autonomous mechanisms in protein-misfolding diseases. Dis Model Mech (2014) 0.92
Genetic manipulations of mutant huntingtin in mice: new insights into Huntington's disease pathogenesis. FEBS J (2013) 0.90
Tracking brain palmitoylation change: predominance of glial change in a mouse model of Huntington's disease. Chem Biol (2013) 0.90
Huntingtin is required for normal excitatory synapse development in cortical and striatal circuits. J Neurosci (2014) 0.87
Huntington's Disease and Striatal Signaling. Front Neuroanat (2011) 0.86
Striatal atrophy and dendritic alterations in a knock-in mouse model of Huntington's disease. Brain Res Bull (2012) 0.86
Enhanced Ca(2+)-dependent glutamate release from astrocytes of the BACHD Huntington's disease mouse model. Neurobiol Dis (2013) 0.86
The choreography of neuroinflammation in Huntington's disease. Trends Immunol (2015) 0.85
Huntington's disease: the past, present, and future search for disease modifiers. Yale J Biol Med (2013) 0.85
Mouse models of polyglutamine diseases: review and data table. Part I. Mol Neurobiol (2012) 0.84
Conditional expression of Parkinson's disease-related R1441C LRRK2 in midbrain dopaminergic neurons of mice causes nuclear abnormalities without neurodegeneration. Neurobiol Dis (2014) 0.84
Restricted transgene expression in the brain with cell-type specific neuronal promoters. Hum Gene Ther Methods (2012) 0.83
Altered excitatory and inhibitory inputs to striatal medium-sized spiny neurons and cortical pyramidal neurons in the Q175 mouse model of Huntington's disease. J Neurophysiol (2015) 0.83
Aging of the NMDA receptor: from a mouse's point of view. Future Neurol (2012) 0.82
The role for alterations in neuronal activity in the pathogenesis of polyglutamine repeat disorders. Neurotherapeutics (2014) 0.82
TRiC subunits enhance BDNF axonal transport and rescue striatal atrophy in Huntington's disease. Proc Natl Acad Sci U S A (2016) 0.81
The chicken or the egg: mitochondrial dysfunction as a cause or consequence of toxicity in Huntington's disease. Mech Ageing Dev (2016) 0.77
Rapamycin prevents the mutant huntingtin-suppressed GLT-1 expression in cultured astrocytes. Acta Pharmacol Sin (2012) 0.75
The N17 domain mitigates nuclear toxicity in a novel zebrafish Huntington's disease model. Mol Neurodegener (2015) 0.75
The heat shock response in neurons and astroglia and its role in neurodegenerative diseases. Mol Neurodegener (2017) 0.75
Aggregation of huntingtin in neuronal intranuclear inclusions and dystrophic neurites in brain. Science (1997) 11.53
Onset and progression in inherited ALS determined by motor neurons and microglia. Science (2006) 9.42
Huntington disease. J Neuropathol Exp Neurol (1998) 6.54
Glutamine repeats and neurodegeneration. Annu Rev Neurosci (2000) 6.06
The relationship between trinucleotide (CAG) repeat length and clinical features of Huntington's disease. Nat Genet (1993) 5.82
Loss of huntingtin-mediated BDNF gene transcription in Huntington's disease. Science (2001) 5.28
The temporal and spatial origins of cortical interneurons predict their physiological subtype. Neuron (2005) 4.90
Neuronal alpha-synucleinopathy with severe movement disorder in mice expressing A53T human alpha-synuclein. Neuron (2002) 4.77
Huntingtin interacts with REST/NRSF to modulate the transcription of NRSE-controlled neuronal genes. Nat Genet (2003) 4.76
Nuclear and neuropil aggregates in Huntington's disease: relationship to neuropathology. J Neurosci (1999) 4.27
DARPP-32: an integrator of neurotransmission. Annu Rev Pharmacol Toxicol (2004) 3.84
Decreased glutamate transport by the brain and spinal cord in amyotrophic lateral sclerosis. N Engl J Med (1992) 3.71
A YAC mouse model for Huntington's disease with full-length mutant huntingtin, cytoplasmic toxicity, and selective striatal neurodegeneration. Neuron (1999) 3.50
Identification of two distinct progenitor populations in the lateral ganglionic eminence: implications for striatal and olfactory bulb neurogenesis. J Neurosci (2003) 3.28
Huntingtin and huntingtin-associated protein 1 influence neuronal calcium signaling mediated by inositol-(1,4,5) triphosphate receptor type 1. Neuron (2003) 3.25
Bergmann glia expression of polyglutamine-expanded ataxin-7 produces neurodegeneration by impairing glutamate transport. Nat Neurosci (2006) 3.05
Expression of mutant huntingtin in glial cells contributes to neuronal excitotoxicity. J Cell Biol (2005) 2.57
Widespread expression of Huntington's disease gene (IT15) protein product. Neuron (1995) 2.29
Early striatal dendrite deficits followed by neuron loss with advanced age in the absence of anterograde cortical brain-derived neurotrophic factor. J Neurosci (2004) 2.16
Molecular analysis and clinical correlations of the Huntington's disease mutation. Lancet (1993) 2.15
Pathological cell-cell interactions elicited by a neuropathogenic form of mutant Huntingtin contribute to cortical pathogenesis in HD mice. Neuron (2005) 2.11
Caspase cleavage of mutant huntingtin precedes neurodegeneration in Huntington's disease. J Neurosci (2002) 2.05
Transient and progressive electrophysiological alterations in the corticostriatal pathway in a mouse model of Huntington's disease. J Neurosci (2003) 1.88
Huntingtin forms toxic NH2-terminal fragment complexes that are promoted by the age-dependent decrease in proteasome activity. J Cell Biol (2003) 1.77
NMDA receptor function in mouse models of Huntington disease. J Neurosci Res (2001) 1.76
Deranged neuronal calcium signaling and Huntington disease. Biochem Biophys Res Commun (2004) 1.72
In vitro analysis of huntingtin-mediated transcriptional repression reveals multiple transcription factor targets. Cell (2005) 1.62
Analysis of the huntingtin gene reveals a trinucleotide-length polymorphism in the region of the gene that contains two CCG-rich stretches and a correlation between decreased age of onset of Huntington's disease and CAG repeat number. Hum Mol Genet (1993) 1.56
Trinucleotide repeat expansions and human genetic disease. Bioessays (1994) 1.55
Multiple pathways contribute to the pathogenesis of Huntington disease. Mol Neurodegener (2006) 1.35
Enhanced striatal NR2B-containing N-methyl-D-aspartate receptor-mediated synaptic currents in a mouse model of Huntington disease. J Neurophysiol (2004) 1.32
Morphological and electrophysiological characterization of abnormal cell types in pediatric cortical dysplasia. J Neurosci Res (2003) 1.24
Selective up-regulation of the glial Na+-dependent glutamate transporter GLT1 by a neuroimmunophilin ligand results in neuroprotection. Neurobiol Dis (2005) 1.23
Caspase-3 cleaves and inactivates the glutamate transporter EAAT2. J Biol Chem (2006) 1.21
Striatal neuronal apoptosis is preferentially enhanced by NMDA receptor activation in YAC transgenic mouse model of Huntington disease. Neurobiol Dis (2005) 1.19
Juvenile onset Huntington's disease--clinical and research perspectives. Ment Retard Dev Disabil Res Rev (2001) 1.18
Alterations in N-methyl-D-aspartate receptor sensitivity and magnesium blockade occur early in development in the R6/2 mouse model of Huntington's disease. J Neurosci Res (2005) 1.15
Expression of the Huntington's disease (IT15) protein product in HD patients. Hum Mol Genet (1995) 1.15
The selective vulnerability of striatopallidal neurons. Prog Neurobiol (1999) 1.13
Transcriptional dysregulation in striatal projection- and interneurons in a mouse model of Huntington's disease: neuronal selectivity and potential neuroprotective role of HAP1. Hum Mol Genet (2004) 1.12
Altered cortical glutamate receptor function in the R6/2 model of Huntington's disease. J Neurophysiol (2005) 1.06
Neurobiology of Huntington's disease. Neurobiol Dis (1996) 1.00
Altered striatal amino acid neurotransmitter release monitored using microdialysis in R6/1 Huntington transgenic mice. Eur J Neurosci (2001) 1.00
Mutation size and age at onset in Huntington's disease. J Med Genet (1993) 0.99
Axonal degeneration induced by targeted expression of mutant human tau in oligodendrocytes of transgenic mice that model glial tauopathies. J Neurosci (2005) 0.98
Role of NR2B-type NMDA receptors in selective neurodegeneration in Huntington disease. Neurobiol Aging (2003) 0.97
Complex alteration of NMDA receptors in transgenic Huntington's disease mouse brain: analysis of mRNA and protein expression, plasma membrane association, interacting proteins, and phosphorylation. Neurobiol Dis (2003) 0.97
Changes in expression of N-methyl-D-aspartate receptor subunits occur early in the R6/2 mouse model of Huntington's disease. Dev Neurosci (2006) 0.83
Partial resistance to malonate-induced striatal cell death in transgenic mouse models of Huntington's disease is dependent on age and CAG repeat length. J Neurochem (2001) 0.82
A call for transparent reporting to optimize the predictive value of preclinical research. Nature (2012) 14.63
Genome-wide analysis of clustered Dorsal binding sites identifies putative target genes in the Drosophila embryo. Proc Natl Acad Sci U S A (2001) 6.39
The clinicopathologic spectrum of focal cortical dysplasias: a consensus classification proposed by an ad hoc Task Force of the ILAE Diagnostic Methods Commission. Epilepsia (2010) 6.23
Towards a transgenic model of Huntington's disease in a non-human primate. Nature (2008) 4.47
Parkin-deficient mice exhibit nigrostriatal deficits but not loss of dopaminergic neurons. J Biol Chem (2003) 4.36
Selective striatal neuronal loss in a YAC128 mouse model of Huntington disease. Hum Mol Genet (2003) 4.07
FACS-array profiling of striatal projection neuron subtypes in juvenile and adult mouse brains. Nat Neurosci (2006) 3.81
Shadow enhancers as a source of evolutionary novelty. Science (2008) 3.71
Full-length human mutant huntingtin with a stable polyglutamine repeat can elicit progressive and selective neuropathogenesis in BACHD mice. J Neurosci (2008) 3.54
Heterosynaptic dopamine neurotransmission selects sets of corticostriatal terminals. Neuron (2004) 3.16
Huntingtin-protein interactions and the pathogenesis of Huntington's disease. Trends Genet (2004) 2.88
Early and progressive sensorimotor anomalies in mice overexpressing wild-type human alpha-synuclein. J Neurosci (2004) 2.64
The prolyl isomerase Pin1 regulates amyloid precursor protein processing and amyloid-beta production. Nature (2006) 2.61
Expression of mutant huntingtin in glial cells contributes to neuronal excitotoxicity. J Cell Biol (2005) 2.57
Serines 13 and 16 are critical determinants of full-length human mutant huntingtin induced disease pathogenesis in HD mice. Neuron (2009) 2.43
Paused Pol II coordinates tissue morphogenesis in the Drosophila embryo. Cell (2013) 2.42
Dietary restriction normalizes glucose metabolism and BDNF levels, slows disease progression, and increases survival in huntingtin mutant mice. Proc Natl Acad Sci U S A (2003) 2.35
Systematic behavioral evaluation of Huntington's disease transgenic and knock-in mouse models. Neurobiol Dis (2009) 2.29
Promoter elements associated with RNA Pol II stalling in the Drosophila embryo. Proc Natl Acad Sci U S A (2008) 2.25
Identifying polyglutamine protein species in situ that best predict neurodegeneration. Nat Chem Biol (2011) 2.24
Mutant huntingtin causes context-dependent neurodegeneration in mice with Huntington's disease. J Neurosci (2003) 2.20
Interaction of Huntington disease protein with transcriptional activator Sp1. Mol Cell Biol (2002) 2.19
N-terminal mutant huntingtin associates with mitochondria and impairs mitochondrial trafficking. J Neurosci (2008) 2.18
Pathological cell-cell interactions elicited by a neuropathogenic form of mutant Huntingtin contribute to cortical pathogenesis in HD mice. Neuron (2005) 2.11
Properties of developmental gene regulatory networks. Proc Natl Acad Sci U S A (2008) 2.05
Huntingtin phosphorylation acts as a molecular switch for anterograde/retrograde transport in neurons. EMBO J (2008) 2.03
An antisense CAG repeat transcript at JPH3 locus mediates expanded polyglutamine protein toxicity in Huntington's disease-like 2 mice. Neuron (2011) 2.00
Assessment and surgical outcomes for mild type I and severe type II cortical dysplasia: a critical review and the UCLA experience. Epilepsia (2009) 1.99
The corticostriatal pathway in Huntington's disease. Prog Neurobiol (2006) 1.99
Interaction of Huntingtin-associated protein-1 with kinesin light chain: implications in intracellular trafficking in neurons. J Biol Chem (2005) 1.98
Neuroprotective role of Sirt1 in mammalian models of Huntington's disease through activation of multiple Sirt1 targets. Nat Med (2011) 1.97
Transient and progressive electrophysiological alterations in the corticostriatal pathway in a mouse model of Huntington's disease. J Neurosci (2003) 1.88
Expression of mutant huntingtin in mouse brain astrocytes causes age-dependent neurological symptoms. Proc Natl Acad Sci U S A (2009) 1.87
Hypothalamic huntingtin-associated protein 1 as a mediator of feeding behavior. Nat Med (2006) 1.86
Repeated exposure to methamphetamine causes long-lasting presynaptic corticostriatal depression that is renormalized with drug readministration. Neuron (2008) 1.81
Huntingtin forms toxic NH2-terminal fragment complexes that are promoted by the age-dependent decrease in proteasome activity. J Cell Biol (2003) 1.77
How the Dorsal gradient works: insights from postgenome technologies. Proc Natl Acad Sci U S A (2008) 1.70
Accumulation of N-terminal mutant huntingtin in mouse and monkey models implicated as a pathogenic mechanism in Huntington's disease. Hum Mol Genet (2008) 1.70
DNA hypomethylation restricted to the murine forebrain induces cortical degeneration and impairs postnatal neuronal maturation. Hum Mol Genet (2009) 1.68
Transgenic rat model of Huntington's disease. Hum Mol Genet (2003) 1.66
Comprehensive identification of Drosophila dorsal-ventral patterning genes using a whole-genome tiling array. Proc Natl Acad Sci U S A (2006) 1.66
Polyglutamine expansion of huntingtin impairs its nuclear export. Nat Genet (2005) 1.62
Genetic mouse models of Huntington's and Parkinson's diseases: illuminating but imperfect. Trends Neurosci (2004) 1.58
Adenosine A(2A) receptor mediates microglial process retraction. Nat Neurosci (2009) 1.56
Spatial regulation of microRNA gene expression in the Drosophila embryo. Proc Natl Acad Sci U S A (2005) 1.55
Deletion of astroglial Dicer causes non-cell-autonomous neuronal dysfunction and degeneration. J Neurosci (2011) 1.52
Impaired ubiquitin-proteasome system activity in the synapses of Huntington's disease mice. J Cell Biol (2008) 1.51
Differential electrophysiological properties of dopamine D1 and D2 receptor-containing striatal medium-sized spiny neurons. Eur J Neurosci (2008) 1.49
Early motor dysfunction and striosomal distribution of huntingtin microaggregates in Huntington's disease knock-in mice. J Neurosci (2002) 1.48
Dopamine enhancement of NMDA currents in dissociated medium-sized striatal neurons: role of D1 receptors and DARPP-32. J Neurophysiol (2002) 1.47
Polyglutamine domain modulates the TBP-TFIIB interaction: implications for its normal function and neurodegeneration. Nat Neurosci (2007) 1.46
Age-dependent alterations of corticostriatal activity in the YAC128 mouse model of Huntington disease. J Neurosci (2009) 1.43
Differential activities of the ubiquitin-proteasome system in neurons versus glia may account for the preferential accumulation of misfolded proteins in neurons. J Neurosci (2008) 1.41
Differential susceptibility to excitotoxic stress in YAC128 mouse models of Huntington disease between initiation and progression of disease. J Neurosci (2009) 1.40
Contribution of nuclear and extranuclear polyQ to neurological phenotypes in mouse models of Huntington's disease. Hum Mol Genet (2005) 1.39
Network organization of the huntingtin proteomic interactome in mammalian brain. Neuron (2012) 1.38
Multiple pathways contribute to the pathogenesis of Huntington disease. Mol Neurodegener (2006) 1.35
Lack of huntingtin-associated protein-1 causes neuronal death resembling hypothalamic degeneration in Huntington's disease. J Neurosci (2003) 1.35
Where do you think you are going? The NMDA-D1 receptor trap. Sci STKE (2006) 1.34
Expression of Huntington's disease protein results in apoptotic neurons in the brains of cloned transgenic pigs. Hum Mol Genet (2010) 1.33
Epileptogenesis in pediatric cortical dysplasia: the dysmature cerebral developmental hypothesis. Epilepsy Behav (2006) 1.32
Striatal potassium channel dysfunction in Huntington's disease transgenic mice. J Neurophysiol (2004) 1.30
Genetic control of instrumental conditioning by striatopallidal neuron-specific S1P receptor Gpr6. Nat Neurosci (2007) 1.30
Characterization of a brain-enriched chaperone, MRJ, that inhibits Huntingtin aggregation and toxicity independently. J Biol Chem (2002) 1.29
Alterations in cortical excitation and inhibition in genetic mouse models of Huntington's disease. J Neurosci (2009) 1.28
Differential electrophysiological changes in striatal output neurons in Huntington's disease. J Neurosci (2011) 1.27